Speakers from Touchstone Exploration, Shanta Gold, Savannah Resources and Kavango Resources feature in our Natural Resources webinar on May 25th. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,355.60
Bid: 1,354.60
Ask: 1,355.00
Change: 11.40 (0.85%)
Spread: 0.40 (0.03%)
Open: 1,347.00
High: 1,358.80
Low: 1,345.00
Yest. Close: 1,344.20
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

European Regulator Approves Glaxo's Blood Cancer Treatment Blenrep

Wed, 26th Aug 2020 19:32

(Alliance News) - GlaxoSmithKline PLC on Wednesday said that the European Commission has granted conditional marketing authorisation for Blenrep, or belantamab mafodotin, as monotherapy for the treatment of multiple myeloma, a type of blood cancer.

Multiple myeloma is a cancer that forms in a type of white blood cell called a plasma cell.

Blenrep was approved for adults who have received at least four prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.

The Brentford, England-based company said that the approval is based on data from the Driving Excellence in Approaches to Multiple Myeloma study including a 13-month follow-up data.

The study data demonstrated that treatment with single-agent Blenrep resulted in an overall response rate of 32%. The median duration of response was 11 months and median overall survival was 13.7 months.

Earlier in August, the US Food & Drug Administration approved Blenrep as a monotherapy treatment for adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies.

Shares in Glaxo on Wednesday closed 0.5% lower at 1,510.80 pence each in London on Wednesday.

By Tapan Panchal; tapanpanchal@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News

IN BRIEF: EMA starts rolling review of Covid treatment by GSK and Vir

IN BRIEF: EMA starts rolling review of Covid treatment by GSK and Vir

Today 14:08

CureVac says well on track to request vaccine approval as planned

* Says infections rate within trial population is high* Some doses aimed for production in '21 to be delivered in '22* Trial result will also offer unique view on spread of variantsBy Ludwig BurgerFRANKFURT, May 5 (Reuters) - Germany's CureVac is ...

5 May 21 15:54

UK prosecutor ends investigation into Airbus individuals - sources

By Kirstin RidleyLONDON, May 4 (Reuters) - Britain's Serious Fraud Office (SFO) has ended a criminal investigation into individuals associated with Airbus, the European planemaker that agreed to a record $4.0 billion global settlement 16 months ag...

4 May 21 16:34

GSK's ViiV says HIV drug gets rolling probe from US watchdog

GSK's ViiV says HIV drug gets rolling probe from US watchdog

4 May 21 14:29

Sunday newspaper round-up: GlaxoSmithKline, Rare Earths, Amazon

(Sharecast News) - Top investors in Glaxo Smith Kline are piling pressure on Dame Emma Walmsley after the activist New York hedge fund Elliott Management was revealed to have built a significant stake. Two top-20 investors in the drugs and consumer goods giant said that the chief executive's future was in doubt after four years of disappointing performance. One top-20 investor said there was "no desire to protect her" among institutional shareholders. Another said that Walmsley, 51, should step aside after her plan to break the business in two is carried out and hand over to her lieutenant, Luke Miels. - Sunday Times

2 May 21 12:32

LONDON MARKET MIDDAY: Eurozone recession and Barclays slide quash gain

LONDON MARKET MIDDAY: Eurozone recession and Barclays slide quash gain

30 Apr 21 12:13

BROKER RATINGS: Johnson Matthey and Meggitt receive upgrades

BROKER RATINGS: Johnson Matthey and Meggitt receive upgrades

30 Apr 21 09:43

LONDON MARKET CLOSE: Stocks subdued ahead of US Fed rate decision

LONDON MARKET CLOSE: Stocks subdued ahead of US Fed rate decision

28 Apr 21 17:01

UK shareholder meetings calendar - next 7 days

UK shareholder meetings calendar - next 7 days

28 Apr 21 16:06

TOP NEWS: GSK reports first quarter revenue drop amid Covid-19 impact

TOP NEWS: GSK reports first quarter revenue drop amid Covid-19 impact

28 Apr 21 12:40

GSK sticks to guidance after crisis hits profit and revenue

(Sharecast News) - GlaxoSmithKline stuck to its annual guidance after the Covid-19 crisis caused profit and revenue to fall in the first quarter of 2021.

28 Apr 21 12:23

UPDATE 1-GSK exceeds earnings expectations despite sales falling short

(Adds details on earnings, outlook)April 28 (Reuters) - GSK topped analysts' expectations for first-quarter earnings as more people visited clinics for critical treatments such as HIV and routine shots once COVID-19 curbs eased, adding on Wednesda...

28 Apr 21 12:20

UPDATE 2-GSK focused on split as COVID curb easing helps earnings

(Recasts, adds details, CEO quote)By Pushkala Aripaka and Ludwig BurgerApril 28 (Reuters) - GSK confirmed plans to split in two were "well underway" on Wednesday after exceeding analysts' first-quarter earnings forecasts as an easing of COVID-19 cu...

28 Apr 21 12:20

UPDATE 3-GSK pursuing split as easing of COVID curbs aids earnings

(Adds details, analyst reaction)By Pushkala Aripaka and Ludwig BurgerApril 28 (Reuters) - Plans for GlaxoSmithKline to split in two are "well underway" it said on Wednesday after exceeding first-quarter earnings forecasts as an easing of COVID-19 ...

28 Apr 21 12:20

UPDATE 4-GSK focused on split as cost checks, COVID-19 easings aid earnings

* CEO says focused on seeing split through, big picture* COVID-19 pandemic still taking toll on overall business* GSK expects recovery in vaccine sales in H2* Shares marginally higher following Q1 results release (Adds details on sales, analyst comm...

28 Apr 21 12:20

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.